Corporate Profile

Unum Therapeutics is a biopharmaceutical company focused on developing novel precision kinase inhibitors to treat a broad range of patients with unmet medical needs. Unum’s PLX9486 is a highly selective and potent KIT mutant inhibitor with a potentially best-in-class clinical profile that inhibits KIT D816V mutations in patients with GIST or Systemic Mastocytosis. 

By inhibiting primary KIT mutations as well as resistance and activation loop mutations, PLX9486 fills an unmet need for patients living with GIST or Systemic Mastocytosis, with the potential to greatly increase their chance of survival and improve quality of life.

News Releases